Pages
Products
mRFP AAV (Serotype 8)

mRFP AAV (Serotype 8)

Cat.No. :  AAV00101Z

Titer: ≥1x10^12 GC/mL / ≥1x10^13 GC/mL Size: 30 ul/100 ul/500 ul/1 ml

Serotype:  AAV Serotype 8 Storage:  -80 ℃

Inquire for Price

AAV Particle Information

Quality Control

Cat. No. AAV00101Z
Description mRFP AAV (Serotype 8) is the serotype 8 rAAV which expresses mRFP under the CMV promoter. mRFP AAV (Serotype 8) express a monomeric red fluorescent protein mutant from Discosoma (DsRed), overcome the tetramerization which is toxic to cells. mRFP can be used as a reporter in target cells. Used as a control.
Reporter mRFP
Serotype AAV Serotype 8
Product Type Adeno-associated virus
Application

1. Determination of optimal MOI (multiplicity of infection), administration methods etc.

2. Detection of the infection efficiency of the AAV serotype against a specific cell type or tissue.

3. Using reporter genes to visualize the distribution and expression of AAV vectors in live animals, helping assess the biodistribution and persistence of gene delivery.

Titer Varies lot by lot, typically ≥1x10^12 GC/mL
Size Varies lot by lot, for example, 30 μL, 50 μL, 100 μL etc.
Storage Store at -80℃. Avoid multiple freeze/thaw cycles.
Shipping Frozen on dry ice
Creative Biogene ensures high-quality AAV particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between AAV particle lots.
Endotoxin Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in the production of AAV, especially for applications in animal studies and gene therapy. Effective endotoxin quality control is essential in the development and manufacturing of AAV particles. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced AAV particles to ensure regulatory compliance.
Purity AAV purity is critical for ensuring the safety and efficacy of AAV-based applications.AAV capsids are composed of three main protein components, known as viral proteins: VP1, VP2, and VP3. These proteins play a critical role in the structure and functionality of the AAV capsid. Monitoring the VP1, VP2, and VP3 content in AAV preparations is essential for quality control in AAV production. Our AAV particles are tested for showing three clear bands of VP1, VP2 VP3 by SDS-PAGE.
Sterility The AAV virus samples are inoculated into the cell culture medium for about 5 days to detect bacterial and fungal growth.
Transducibility Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of AAV to deliver genetic material into target cells or tissues, and assess gene expression and functional activities.
Empty vs. Full Capsids Based-on our proprietary AAV production and purification technology, Creative Biogene can always offer AAV particles with high ratio of full capsids. If required, we can also assess the ratio for a specifc lot of AAV particles by transmission electron microscopy (TEM) or other methods.
Quick Inquiry

Background

Publications

Q & A

Customer Reviews

Gene therapy is the introduction of target genes into target cells to replace or repair defective genes and correct genetic diseases. The key to disease treatment lies in gene delivery vectors. At present, commonly used vectors are divided into viral vectors and non-viral vectors. Among the gene delivery vectors currently used in clinical trials, viral vectors account for more than 70%, and the most successful delivery vectors include retroviruses, lentiviruses, adenoviruses, and adeno-associated viruses (AAV). Compared with other viral vectors, AAV requires a lower viral load and can be used to treat certain rare diseases. This vector is usually used in non-dividing target cells such as liver, nervous system, eye, and skeletal muscle cells. The advantage of using this vector is that once delivered, the DNA it carries can exist in a free form in the patient's body for a long time, even for life, without causing potential insertion mutations in the host cell genome, thereby improving the safety of gene therapy. In addition, different AAV serotypes have specific affinities for different tissues, so they can be used in therapeutic designs for different target organs.
Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
User-Friendly Protocol

Even for those new to AAV vectors, the detailed instructions ensure a smooth application process, minimizing guesswork and saving valuable time in the lab.

Canada

09/23/2020

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction